Cargando…

Correction to: Damoctocog Alfa Pegol: A Review in Haemophilia A

Detalles Bibliográficos
Autores principales:	Paik, Julia, Deeks, Emma D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728279/ https://www.ncbi.nlm.nih.gov/pubmed/31444769 http://dx.doi.org/10.1007/s40265-019-01190-1

Ejemplares similares

Damoctocog Alfa Pegol: A Review in Haemophilia A
por: Paik, Julia, et al.
Publicado: (2019)

Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey
por: Zanon, Ezio
Publicado: (2023)

Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A
por: Vashi, Parth, et al.
Publicado: (2021)

Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A
por: Sanabria, Martin, et al.
Publicado: (2021)

PROTECT VIII kids extension study: Long‐term safety and efficacy of BAY 94‐9027 (damoctocog alfa pegol) in children with severe haemophilia A
por: Mancuso, Maria Elisa, et al.
Publicado: (2021)

Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study
por: Reding, Mark T., et al.
Publicado: (2023)

Correction to: Nonacog Beta Pegol: A Review in Haemophilia B
por: Syed, Yahiya Y.
Publicado: (2018)

Correction to: Efmoroctocog Alfa: A Review in Haemophilia A
por: Frampton, James E.
Publicado: (2021)

Correction to: Eftrenonacog Alfa: A Review in Haemophilia B
por: Lamb, Yvette N., et al.
Publicado: (2023)

Nonacog Beta Pegol: A Review in Haemophilia B
por: Syed, Yahiya Y.
Publicado: (2017)

Lonoctocog Alfa: A Review in Haemophilia A
por: Al-Salama, Zaina T., et al.
Publicado: (2017)

Efmoroctocog Alfa: A Review in Haemophilia A
por: Frampton, James E.
Publicado: (2021)

Eftrenonacog Alfa: A Review in Haemophilia B
por: Lamb, Yvette N., et al.
Publicado: (2023)

Correction to: Vestronidase Alfa: A Review in Mucopolysaccharidosis VII
por: McCafferty, Emma H., et al.
Publicado: (2019)

Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40°C
por: Napolitano, Mariasanta, et al.
Publicado: (2021)

Correction to: Cladribine Tablets: A Review in Relapsing MS
por: Deeks, Emma D.
Publicado: (2019)

Correction to: Tapentadol Prolonged Release: A Review in Pain Management
por: Deeks, Emma D.
Publicado: (2019)

Correction to: Efanesoctocog Alfa: First Approval
por: Keam, Susan J.
Publicado: (2023)

A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States
por: Aledort, Louis, et al.
Publicado: (2020)

Correction to: Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data
por: Dattola, Annunziata, et al.
Publicado: (2017)

Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa
por: Lissitchkov, Toshko, et al.
Publicado: (2023)

Correction to: Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection
por: Deeks, Emma D.
Publicado: (2019)

Correction to: Andexanet Alfa: First Global Approval
por: Heo, Young-A
Publicado: (2018)

Correction to: Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia
por: Tiede, Andreas, et al.
Publicado: (2018)

Thrombogenicity evaluation in 221 patients with haemophilia B treated with nonacog alfa
por: Rendo, Pablo, et al.
Publicado: (2018)

Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B
por: Mahlangu, Johnny, et al.
Publicado: (2021)

Perioperative haemostasis with full‐length, PEGylated, recombinant factor VIII with extended half‐life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single‐arm phase III trial
por: Gruppo, Ralph, et al.
Publicado: (2019)

Correction to: Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer
por: Kang, Connie, et al.
Publicado: (2019)

Correction to: Odevixibat: First Approval
por: Deeks, Emma D.
Publicado: (2021)

Correction to: Ozanimod: A Review in Ulcerative Colitis
por: Paik, Julia
Publicado: (2022)

Correction to: Sarecycline: First Global Approval
por: Deeks, Emma D.
Publicado: (2019)

Correction to: GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2018)

Correction to: Polatuzumab Vedotin: First Global Approval
por: Deeks, Emma D.
Publicado: (2019)

Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials
por: Tosetto, Alberto, et al.
Publicado: (2020)

An overview of turoctocog alfa pegol (N8‐GP; ESPEROCT(®)) assay performance: Implications for postadministration monitoring
por: Ezban, Mirella, et al.
Publicado: (2019)

Correction to: Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use
por: Heo, Young-A
Publicado: (2023)

The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A
por: Male, Christoph, et al.
Publicado: (2022)

Correction to: Abrocitinib: First Approval
por: Deeks, Emma D., et al.
Publicado: (2022)

Correction to: Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus
Publicado: (2022)

Correction to: Afatinib in advanced NSCLC: a profile of its use
por: Deeks, Emma D., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nm4hpeh1e8fd773aql1vn56v6q